TG Therapeutics (TGTX) Peer Comparison
$55.97
$-0.47
(-0.83%)
As on 28-Oct-2026 11:35EDT
Market cap
$8,293 Mln
Revenue (TTM)
$800 Mln
P/E Ratio
19.7
P/B Ratio
14.1
Div. Yield
0 %
Edit
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
8,293 | 18,719 | 15,989 | 16,015 | 14,259 |
Revenue ($ Mln) |
800 | 2,838 | 2,436 | 1,054 | 1,664 |
Net Profit ($ Mln) |
441.49 | 517.83 | 860.62 | 755.85 | 413.60 |
Net Margin (%) |
55.22 | 18.24 | 35.33 | 71.69 | 24.86 |
RoE (%) |
70.52 | 87.53 | 42.98 | -- | 430.03 |
Price to Earnings |
19.70 | 37.16 | 20.36 | 18.65 | 36.73 |
Price-To-Book |
14.15 | 39.67 | 7.82 | 9.82 | 25.20 |
Income Statement ($ Mln)
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
799.54 | 2,838.39 | 2,435.92 | 1,054.37 | 1,663.74 |
|
Cost of Revenue
|
141.00 | 2,011.22 | 85.67 | 103.47 | 292.42 |
|
Gross Profit
|
515.57 | 760.62 | 2,236.43 | 588.53 | 1,167.84 |
|
Operating Expenses
|
522.21 | 220.03 | 1,378.74 | 841.45 | 440.53 |
|
Operating Profit (EBIT)
|
136.33 | 607.14 | 971.51 | 109.45 | 930.79 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
101.60 | 626.99 | 1,035.47 | 101.11 | 583.34 |
|
Provision for Tax
|
-339.89 | 109.17 | 174.84 | -654.74 | 169.74 |
|
Profit after Tax (Net Income)
|
441.49 | 517.83 | 860.62 | 755.85 | 413.60 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
604.08 | 584.94 | 1,843.76 | 1,435.90 | 143.54 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
767.05 | 221.56 | 288.55 | 384.48 | 2,089.43 |
|
Current Liabilities
|
268.49 | 1,496.10 | 361.93 | 464.70 | 344.44 |
|
Total Liabilities
|
1,063.25 | 1,975.47 | 2,844.42 | 1,302.02 | 2,525.32 |
Assets ($ Mln)
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
493.94 | 1,057.60 | 1,243.41 | 895.24 | 1,644.38 |
|
Current Assets
|
1,145.69 | 1,245.00 | 1,250.82 | 1,389.84 | 933.02 |
|
Total Assets
|
1,063.25 | 1,975.47 | 2,844.42 | 1,302.02 | 2,525.32 |
|
Total Debt*
|
754.44 | 146.04 | 165.93 | 449.89 | 2,146.65 |
|
Net Current Assets
|
877.19 | 0.00 | 888.90 | 925.52 | 588.59 |
Cashflow ($ Mln)
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-24.77 | 713.22 | 884.27 | 51.77 | 651.56 |
|
Cash Flow from Investing Activities
|
13.80 | -31.14 | 350.44 | -8.15 | -545.81 |
|
Cash from Financing Activities
|
-89.73 | -860.39 | -969.59 | 34.89 | -85.17 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
64.58 | 57.43 | 32.82 | -30.01 | 15.61 |
|
ROE (%)
|
70.52 | 87.53 | 42.98 | 163.18 | 430.03 |
|
ROA (%)
|
31.73 | 15.73 | 29.32 | 31.68 | 16.19 |
|
EBIT Margin (%)
|
16.75 | 21.70 | 41.82 | 5.73 | 36.28 |
|
Net Margin (%)
|
55.22 | 18.24 | 35.33 | 71.69 | 24.86 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
76.08 | 20.35 | 9.23 | 114.85 | 41.15 |
|
EBIT Growth (%)
|
37.43 | 18.61 | 29.37 | 136.39 | -14.99 |
|
Net Profit Growth (%)
|
630.24 | 19.59 | 42.89 | 378.76 | -25.78 |
|
EPS Growth (%)
|
633.67 | 28.06 | 50.42 | 353.27 | -23.48 |
|
Book Value Growth (%)
|
125.86 | 108.60 | -0.70 | 816.12 | -55.81 |
Valuation Ratios
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
10.62 | 36.06 | 15.79 | -59.76 | 24.99 |
|
Price / Book Value
|
7.33 | 35.44 | 5.72 | -80.42 | 162.23 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
36.24 | 27.88 | 12.44 | -121.54 | 17.31 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.23 | 0.00 | 0.00 | 0.27 | 13.50 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.00 | 0.05 | 1.46 |
|
Current Ratio
|
4.27 | 0.83 | 3.46 | 2.99 | 2.71 |
|
Quick Ratio
|
3.72 | 0.83 | 3.38 | 2.32 | 2.31 |
|
Interest Coverage
|
3.71 | -- | -- | 1.62 | 29.73 |
Operating Efficiency Ratios
| TG Therapeutics (TGTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
50.22 | 15.77 | 13.74 | 21.25 | 27.40 |
|
Asset Turnover
|
0.57 | 0.86 | 0.83 | 0.44 | 0.65 |
|
Receivable days
|
128.85 | 50.42 | 43.48 | 85.52 | 98.04 |
|
Inventory Days
|
428.02 | -- | 96.17 | 1,056.70 | 254.12 |
|
Payable days
|
300.65 | 6.26 | 147.97 | 331.01 | 24.86 |
|
Cash Conversion Cycle
|
256.22 | -- | -8.32 | 811.21 | 327.29 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
